Vudalimab

沃达利单抗

Report date: 2026/03/14 20:00:17

Base Information

Drug NameVudalimab
Drug Alias NamePD-1 x CTLA-4 (Xencor)XmAb-20717XmAb-717XmAb 717
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Multispecific monoclonal antibody > Bispecific monoclonal antibody
Mechanisms of ActionAntibody-dependent cell-mediated cytotoxicity (ADCC) effectsCytotoxic T-Lymphocyte-Associated Antigen 4 inhibitorsProgrammed death-ligand 1 blockers +[4] 
TargetsCytotoxic T-Lymphocyte-Associated Antigen 4Programmed death-ligand 1
Therapy Area/IndicationsGastroesophageal Junction NeoplasmsCastration-Sensitive Prostate NeoplasmsSolid tumours +[37] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryBelgiumUnited StatesTaiwan +[8] 
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaN/A
Originator CompaniesXencor Inc
China Registration ClassN/A

Develop Information

Active CompaniesXencor IncNorthwestern University
Inactive CompaniesThe University Of Texas MD Anderson Cancer CenterEmory University
Active IndicationsGastroesophageal Junction NeoplasmsSolid tumoursAdnexal Diseases +[31] 
Inactive IndicationsCastration-Sensitive Prostate NeoplasmsProstatic NeoplasmsCarcinoma, Non-Small-Cell Lung +[6] 

Other Information

ATC CodeN/A
Related LinksN/A